Welcome to our home for news – the latest headlines, all in one place. Click through to view a selection of our media coverage, industry news, videos and more.
Botanix Executive Chairman Vince Ippolito will be a featured presenter on Tuesday, 9 September at the HC Wainwright 27th Annual Global Investment Conference in New York, NY (US). This conference attracts institutional fund managers from around the world and some of the most promising global growth companies, including those in the healthcare and life sciences sectors.
https://botanixpharma.com/wp-content/uploads/HC-Wainwright.png8501600Haley Chartres/wp-content/uploads/botanix-logo.pngHaley Chartres2025-09-08 00:41:182025-09-08 00:41:18Botanix featured at global investor conference
Botanix announced that Dongwha Pharm. Co., Ltd. has received regulatory approval for ECCLOCK® gel, 5% (Sofpironium Bromide) in South Korea. Dongwha is a sublicensee of Botanix’s Japanese partner, Kaken Pharmaceutical Co. Ltd.
Dongwha – Korea’s first and oldest pharmaceutical company – will commercialise ECCLOCK in the Korean market and add the product to its extensive range of prescription and over-the-counter products.
https://botanixpharma.com/wp-content/uploads/Korea.png8501600Haley Chartres/wp-content/uploads/botanix-logo.pngHaley Chartres2025-09-04 23:31:542025-09-12 22:38:16Botanix announces regulatory approval of ECCLOCK® gel, 5% (Sofpironium Bromide) in South Korea
The Annual Report for FY2025 has been released. At year end, Botanix held $64.9 million cash and $15.3 million in undrawn debt. Operating costs are stable with no inventory purchases anticipated in 1H FY2026, and revenue is expected to increase quarterly. The Company is well funded to achieve profitability.
Botanix welcomes Patricia Walker, MD, PhD, to the Board. She brings extensive experience and learnings from previous board affiliations with leading dermatology companies and the insights of a working dermatologist. She has led drug development for numerous key dermatology products, including Sofdra™ (sofpironium), from a preclinical asset to Phase 3 before its acquisition by Botanix.
Botanix Chief Executive Officer Dr Howie McKibbon will be a featured presenter at the Canaccord Genuity 45th Annual Growth Conference in Boston, MA, which attracts institutional fund managers from around the world, and some of the most promising global growth companies, including those in the healthcare and life sciences sectors, will present during the event.
The Quarterly Activity Report and 4C Quarterly Cash Flow Report for Q4 FY2025 have been released. During the quarter, Botanix raised A$40m in capital, established a loan facility of up to the euro equivalent of US$30 million, and ended the quarter with A$64.9m cash. With operating costs stable and revenues expected to rise, Botanix is well funded to support Sofdra™ (sofpironium) to profitability.
Botanix featured at global investor conference
/in Featured, Latest News, News, Presentations /by Haley ChartresBotanix Executive Chairman Vince Ippolito will be a featured presenter on Tuesday, 9 September at the HC Wainwright 27th Annual Global Investment Conference in New York, NY (US). This conference attracts institutional fund managers from around the world and some of the most promising global growth companies, including those in the healthcare and life sciences sectors.
View ASX Release & Presentation.
Botanix announces regulatory approval of ECCLOCK® gel, 5% (Sofpironium Bromide) in South Korea
/in ASX Releases, Featured, Latest News, News /by Haley ChartresBotanix announced that Dongwha Pharm. Co., Ltd. has received regulatory approval for ECCLOCK® gel, 5% (Sofpironium Bromide) in South Korea. Dongwha is a sublicensee of Botanix’s Japanese partner, Kaken Pharmaceutical Co. Ltd.
Dongwha – Korea’s first and oldest pharmaceutical company – will commercialise ECCLOCK in the Korean market and add the product to its extensive range of prescription and over-the-counter products.
Botanix Releases Annual Report
/in ASX Releases, Featured, Latest News, News /by Haley ChartresThe Annual Report for FY2025 has been released. At year end, Botanix held $64.9 million cash and $15.3 million in undrawn debt. Operating costs are stable with no inventory purchases anticipated in 1H FY2026, and revenue is expected to increase quarterly. The Company is well funded to achieve profitability.
View Report.
Dr Patricia Walker Joins Botanix Board
/in ASX Releases, Featured, Latest News, News /by Haley ChartresBotanix welcomes Patricia Walker, MD, PhD, to the Board. She brings extensive experience and learnings from previous board affiliations with leading dermatology companies and the insights of a working dermatologist. She has led drug development for numerous key dermatology products, including Sofdra™ (sofpironium), from a preclinical asset to Phase 3 before its acquisition by Botanix.
View ASX Release
Botanix investor presentation at Canaccord Genuity event
/in ASX Releases, Featured, Latest News, News, Presentations /by Haley ChartresBotanix Chief Executive Officer Dr Howie McKibbon will be a featured presenter at the Canaccord Genuity 45th Annual Growth Conference in Boston, MA, which attracts institutional fund managers from around the world, and some of the most promising global growth companies, including those in the healthcare and life sciences sectors, will present during the event.
Click to view the ASX Release.
Botanix Releases Quarterly Reports
/in ASX Releases, Featured, Latest News /by Haley ChartresThe Quarterly Activity Report and 4C Quarterly Cash Flow Report for Q4 FY2025 have been released. During the quarter, Botanix raised A$40m in capital, established a loan facility of up to the euro equivalent of US$30 million, and ended the quarter with A$64.9m cash. With operating costs stable and revenues expected to rise, Botanix is well funded to support Sofdra™ (sofpironium) to profitability.
Click to view reports.